A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04136444 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures

Conditions

Interventions

Sponsor

UCB Biopharma S.P.R.L.